We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
6
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
FDA
Food and Drug Administration
- Gensco Pharma has acquired global rights and intellectual property for RizaFilm and RizaPort, innovative oral dissolvable film treatments for migraines already approved by FDA and EMA. - The company plans to launch RizaFilm in the U.S. market by Q4 2025 while pursuing international expansion in Asia, the Middle East, and the Americas through licensing partnerships. - The acquisition positions Gensco strategically in the multi-billion-dollar migraine treatment market, addressing unmet patient needs with a water-free administration method for faster relief.
